Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor

被引：82

作者：

Liu, Jie ^{[1
]}

Shiono, Jun ^{[1
]}

Shimizu, Kuniyoshi ^{[1
]}

Kukita, Akiko ^{[2
]}

Kukita, Toshio ^{[3
]}

Kondo, Ryuichiro ^{[1
]}

机构：

[1] Kyushu Univ, Fac Agr, Dept Forest & Forest Prod Sci, Fukuoka 8128581, Japan

[2] Saga Univ, Fac Med, Saga 8498501, Japan

[3] Kyushu Univ, Fac Dent Sci, Higashi Ku, Fukuoka 8128582, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 08期

关键词：

Ganoderma lucidum; Anti-androgen activities; Prostate cancer; Ganoderic acid DM; Androgen receptor; Osteoclast; BONE; 5-ALPHA-REDUCTASE; LIGAND;

D O I：

10.1016/j.bmcl.2009.02.119

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5 alpha-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：2154 / 2157

页数：4

共 28 条

[1]

What patients take without telling you: holistic approach for BPH [J].